All articles by Elliot Gardner

Unreal Engine: from gaming to ground-breaking cures

It generally takes between ten and 12 years to bring a new drug to market, and the initial discovery and…
Hereditary Alzheimer’s: could rare genes hold the key to a cure?

Hereditary disposition towards the development of Alzheimer’s is a concern for many with family members who have lived with the…
Could digital tech unlock billions in savings for pharma companies?

In March, professional services and management consulting company Accenture announced that by investing in digital technologies, the UK pharmaceutical industry…
Tracing the story of mumps: a timeline

The Evolution of Mumps Through History The mumps virus is highly contagious, spreading rapidly, and can lead to complications including…
Award-winning pharma packaging

Launched in 1977 and organised by UBM, Pharmapack Europe has become the pharmaceutical industry’s dedicated packaging, drug delivery, medical device…

Hemophilia B gene therapy race heats up following Fitusiran’s failure

Removing the need for a regular infusion of the missing Factor IX (FIX) is a long-term goal for the treatment…
US drug imports: a recipe for disaster?

Would importing drugs from foreign markets be a good way to improve patient access to medication? It’s a question that…
The gene-silencing approach to cutting cholesterol

High cholesterol is a major problem in the developed world. One of the leading causes of heart disease – and…
Pooling resources for clinical trials

Adaptive clinical trials are becoming increasingly commonplace. Unlike traditional approaches to clinical trials – which lock in the study’s design…
Alzheimer’s drugs: will 2017 bring better news?

Up to this point, clinical trials for Alzheimer’s disease have had an incredibly high failure rate, a combination, researchers say,…